Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection

By LabMedica International staff writers
Posted on 10 Dec 2025

Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. More...

Today, nearly 40 million individuals worldwide live with HIV-1, the strain responsible for most infections. While vaccines are advancing, many candidates induce antibodies that can trigger false-positive HIV tests, making diagnosis and trial interpretation difficult. A new rapid approach now enables clear differentiation between true infection and vaccine-related immune responses.

Researchers at Penn State University (University Park, PA, USA) have developed a point-of-care device that detects both HIV-related proteins and viral RNA to distinguish active infection from vaccine-induced seroreactivity. In collaboration with the HIV Vaccine Trials Network, researchers tested 104 human samples using a 3D-printed diagnostic platform engineered to filter plasma through microchannels and across two test strips simultaneously. One strip detects protein biomarkers generated by antibodies; the other identifies HIV-1 RNA, indicating true viral replication.

The validation, published in Science Advances, showed 95% accuracy in identifying active HIV-1 infection and 98% accuracy in ruling out cases in which vaccine-related immune responses produce false positives. The device’s dual-marker approach outperformed or matched current methods while operating in just five minutes. By incorporating nucleic acid detection, the platform avoids a major limitation of antibody-based diagnostics: the inability to reliably differentiate vaccine effects from true infection.

This technology could support future vaccine trials by minimizing diagnostic uncertainty, simplifying clinical workflows, and improving participant recruitment. Beyond research settings, its scalable and low-cost design carries potential for global deployment, particularly in areas where confirmatory molecular testing is limited. The team plans to enhance device durability, expand its pathogen-screening capability, and explore an at-home viral load testing format for patients receiving antiretroviral therapy.

“By incorporating HIV-1 RNA detection, the testing platform provides a definitive indicator of active viral replication, allowing accurate discrimination between vaccine-induced responses and true infection,” said Dipanjan Pan, PhD, senior author of the study. “Our proposed all-in-one testing platform represents a substantial advancement in HIV diagnostics, enabling accurate detection of active HIV infection while minimizing false positives due to VISP. The scalable design and relatively low cost of the device make it an appealing solution for widespread adoption in both resource-rich and resource-limited environments.”

Related Links:
Penn State University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.